[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367994-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367994-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","current-status-and-future-perspectives-of-molecular-residual-disease-testing-in-genitourinary-cancers-article-review","Current Status and Future Perspectives of Molecular Residual Disease Testing in Genitourinary Cancers - Article Review","","Postoperative recurrence risk after resectable solid tumors makes effective cancer monitoring essential. Molecular residual disease (MRD) denotes microscopic remaining cancer that is not detectable by conventional imaging or pathology. Rapid advances in circulating tumor DNA (ctDNA) analysis using next-generation sequencing enable MRD testing to predict recurrence across cancer types. This review focuses on MRD testing for genitourinary (GU) cancers, summarizing ctDNA-based detection utility and ongoing ctDNA-guided trials.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/current-status-and-future-perspectives-of-molecular-residual-disease-testing-in-genitourinary-cancers-article-review/367994/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/current-status-and-future-perspectives-of-molecular-residual-disease-testing-in-genitourinary-cancers-article-review/367994.png","ImageObject",300,407,{"name":42,"@type":43},"nayy☆","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is molecular residual disease (MRD) in cancer follow-up?","Question",{"text":63,"@type":64},"MRD refers to microscopic cancer that remains undetectable by conventional imaging or pathology after treatment. It supports earlier detection of recurrence risk.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why is circulating tumor DNA (ctDNA) important for MRD testing?",{"text":68,"@type":64},"ctDNA consists of DNA fragments released by tumor cells into the bloodstream. Using next-generation sequencing, ctDNA analysis can identify cancer-related genomic alterations and enable MRD detection with high sensitivity and specificity.",{"name":70,"@type":61,"acceptedAnswer":71},"How can ctDNA-based MRD testing support precision medicine in genitourinary cancers?",{"text":72,"@type":64},"It can personalize cancer monitoring and guide adjuvant therapy decisions, improve early recurrence detection, and refine surveillance strategies. The review also highlights ongoing clinical trials for MRD-guided treatments.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367994,1790198111,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","International Journal of Urology  \nCurrent Status and Future Perspectives of Molecular Residual Disease Testing in Genitourinary Cancers  \nTaigo Kato1 | Shugo Yajima2 | Yoshiaki Nakamura3,4 | Shin Kobayashi5 | Hideaki Miyake6  \n1Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan | 2Department of Urology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan | 3Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Chiba, Japan | 4Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan | 5Department of Hepato-Biliary-Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan | 6Division of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan  \nCorrespondence: Taigo Kato ([kato@uro.med.oaska-u.ac.jp](kato@uro.med.oaska-u.ac.jp))  \nReceived: 14 April 2025 | Revised: 11 August 2025 | Accepted: 17 August 2025  \nKeywords: circulating tumor DNA | genitourinary cancer | molecular residual disease  \nABSTRACT  \nWhile the clinical outcome for patients with resectable solid tumors has improved in recent years, the risk of postoperative recurrence underscores the need for effective monitoring in cancer patients. Molecular residual disease (MRD) refers to the presence of microscopic cancer that remains undetectable on conventional imaging or pathology. Because of the rapid advancement in circulating tumor DNA (ctDNA) analysis using next-generation sequencing technology, MRD testing using ctDNA has demonstrated significant potential for predicting recurrence in various types of cancer. Similar data are found in genitourinary (GU) cancer, and pivotal research has gradually shed light on the importance of MRD in predicting tumor recurrence. To address these critical advancements in MRD testing in GU cancers, we conducted a review of the clinical utility of MRD testing for GU cancers. In this review, we provide an overview of the potential utility of ctDNA-based MRD detection for GU cancers and highlight several ongoing clinical trials for the development of MRD-guided treatments with ctDNA. ctDNA-based MRD testing has the potential to personalize cancer precision medicine in GU cancers, guiding adjuvant therapy decisions, improving early detection of recurrence, and refining surveillance.  \n1 | Introduction  \nGenitourinary (GU) cancers are a group of malignancies that affect the urinary and reproductive systems, including the kidney, bladder, prostate, testicles, and genital organs [1] . Recently, a number of genomic and molecular characterizations have provided insight into the carcinogenesis and progression of GU cancers [2–5] . Although localized GU cancers are generally curable with definitive treatments including surgery, the clinical prognosis of patients with distance metastasis is grim, with the  \n5-year survival rates between 18% and 51%[6], and is dictated by the location and the number of metastases. Considering above, early detection of recurrence can improve the clinical prognosis of GU cancer patients, with the need to develop novel, noninvasive biomarkers for predicting tumor recurrence after surgerybased treatment.  \nLiquid biopsy is becoming an essential resource for providing information on the biological characteristics of cancer with minimum invasiveness, enabling longitudinal and real-time  \n\n| Abbreviations: BC, bladder cancer; BCR, biochemical recurrence; ctDNA, circulating tumor DNA; ddPCR, droplet digital polymerase chain reaction; GU, genitourinary; KC, kidney cancer; LOD, limit of detection; MRD, molecular residual disease; NAC, neoadjuvant chemotherapy; NGS, next-generation sequencing; PC, prostate cancer; RCC, renal cell carcinoma; RFS, recurrence-free survival; RT-PCR, reverse transcription PCR; UC, urothelial carcinoma; UTUC, upper urinary tract carcinoma; VAF, variant allele frequency; WGS, whole-genome sequencing. |\n| --- |\n| This i","cbCaiblVabprPrtl","https://ap.wps.com/l/cbCaiblVabprPrtl","pdf",237621,11,"English","# Introduction\n## MRD and ctDNA rationale in GU cancers\n# Clinical utility of ctDNA-based MRD testing\n## Potential roles in surveillance and adjuvant decision-making\n## Ongoing clinical trials and MRD-guided therapies\n# Conclusion","[{\"question\":\"What is molecular residual disease (MRD) in cancer follow-up?\",\"answer\":\"MRD refers to microscopic cancer that remains undetectable by conventional imaging or pathology after treatment. It supports earlier detection of recurrence risk.\"},{\"question\":\"Why is circulating tumor DNA (ctDNA) important for MRD testing?\",\"answer\":\"ctDNA consists of DNA fragments released by tumor cells into the bloodstream. Using next-generation sequencing, ctDNA analysis can identify cancer-related genomic alterations and enable MRD detection with high sensitivity and specificity.\"},{\"question\":\"How can ctDNA-based MRD testing support precision medicine in genitourinary cancers?\",\"answer\":\"It can personalize cancer monitoring and guide adjuvant therapy decisions, improve early recurrence detection, and refine surveillance strategies. The review also highlights ongoing clinical trials for MRD-guided treatments.\"}]","Current Status and Future Perspectives of Molecular Residual Disease Testing in Genitourinary Cancers - Article Review | PDF",1790174239,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7ce53b485a1a7f817112bb9fc64dc29.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb5dbb00e2c98f43c1ccdf8d5b0612cb.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f845c96f7e3538c1e5da6c859d743d64.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d61b6cf53bcf40eb2392a8b280c9d28.webp",980,1287]